Results 41 to 50 of about 2,250,283 (269)
A rat model of Immunologic and hypertensive kidney injury
Scientific ReportsNon-surgical rodent chronic kidney disease (CKD) models for both glomerular and tubular injuries are currently limited. The current study aimed to develop a rat model of CKD by combining anti-Fx1A with N(ω)-Nitro-L-Arginine Methyl Ester (L-NAME ...
Seo-Kyoung Hwang +10 more
doaj +1 more source
Pharmacoproteomics in drug development [PDF]
The Pharmacogenomics Journal, 2003 The field of proteomics is taking on increased significance as the relevance of investigating and understanding protein expression in disease and drug development is appreciated. Recent advances in proteomics have been driven by the availability of numerous annotated whole-genome sequences and a broad range of technological and bioinformatic ...
Frank A, Witzmann, Raymond A, Grant
openaire +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Leukemia is the most common childhood cancer in Mexico, and acute lymphoblastic leukemia (ALL) is the most frequent subtype. Exposure to high concentrations of benzene has been associated with ALL incidence, particularly in urban areas. This study evaluated the relationship between distance to benzene emission sources and the number
Orlando Rivera Zurita +5 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Adolescents with haematological malignancies face significant emotional and relational challenges, often accompanied by difficulties in communicating their needs within the healthcare context. To address these issues, a narrative‐based psycho‐educational intervention based on the creation and prescription of Ironic Medications was ...
Marta Stoppa +7 more
wiley +1 more source
Scientific ReportsCisplatin-induced nephrotoxicity restricts its clinical use against solid tumors. The present study elucidated the pharmacological effects of Renogrit, a plant-derived prescription medicine, using cisplatin-induced human renal proximal tubular (HK-2 ...
Acharya Balkrishna +7 more
doaj +1 more source
Pharmacogenetics in drug development [PDF]
Philosophical Transactions of the Royal Society B: Biological Sciences, 2005 Over the last two decades, identification of polymorphisms that influence human diseases has begun to have an impact on the provision of medical care. The promise of genetics lies in its ability to provide insights into an individual's susceptibility to disease, the likely nature of the disease and the most appropriate therapy. For much of its history,
Alun D, McCarthy +2 more
openaire +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Platinum‐based chemotherapy is known to cause severe and debilitating hearing loss, but unlike cisplatin, the true incidence of carboplatin‐induced hearing loss remains unclear. We evaluated functional hearing outcomes in children receiving carboplatin to determine the incidence and severity of ototoxicity. Procedure We identified a
Aniket Chawla +6 more
wiley +1 more source
Re‐Irradiation in Pediatric Diffuse Midline Glioma: A Multi‐Institutional Retrospective Study
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Children with recurrent diffuse midline gliomas (DMGs) have limited therapeutic options at recurrence. Re‐irradiation (RT2) may be used at progression, but with uncertainty about the benefit. Methods We conducted a multi‐institutional retrospective study of children aged < 18 with DMG treated at three centers (Toronto, Canada ...
Ajay Thomas Alex +13 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko +19 more
wiley +1 more source
Biomarkers in drug development
Annals of Oncology, 2008 Due to the increasing understanding of the mechanisms relevant to the genesis of cancer, we are experiencing a transition from diseaseto target-oriented therapy. Thus the challenge of bringing new therapeutics to clinical application and registration now focuses on the molecular target expressed by the malignant cell rather than treatment of the ...
openaire +2 more sources